Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. - Saura, C.; Cortés, J.; Modi, S.; Kim, S.-B.; Hamilton, E.; Hurvitz, S.A.; Krop, I.E.; Curigliano, G.; Iwata, H.; Im, S.-A.; Herbolsheimer, P.; Karnoub, M.; et al. (Annals of Oncology, 2026)